Trial Profile
A phase II study of carboplatin/paclitaxel/bevacizumab [Avastin] in resected NSCLC [non-small cell lung cancer]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2005
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Dec 2005 New trial record.